tiprankstipranks
Trending News
More News >
Claritev Corporation (CTEV)
:CTEV
US Market

Claritev (CTEV) AI Stock Analysis

Compare
268 Followers

Top Page

CT

Claritev

(NYSE:CTEV)

Rating:50Neutral
Price Target:
$39.00
▼(-1.42%Downside)
Claritev's stock score is influenced primarily by its financial struggles, with negative profitability and high leverage posing significant risks. The technical analysis is positive, showing strong momentum, but caution is advised due to overbought conditions. Valuation remains a concern with negative profitability, and corporate support adds some positive sentiment.

Claritev (CTEV) vs. SPDR S&P 500 ETF (SPY)

Claritev Business Overview & Revenue Model

Company DescriptionClaritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.
How the Company Makes MoneyMultiPlan makes money primarily through service fees charged to healthcare payers, such as insurance companies and government programs, for using its cost management and payment integrity solutions. The company generates revenue by providing access to its extensive healthcare provider networks, which helps clients reduce costs through negotiated discounts. Additionally, MultiPlan earns money by offering analytics and insights that enhance payment accuracy and efficiency. Significant partnerships with insurance companies and healthcare providers are crucial to its business model, allowing MultiPlan to leverage its network to deliver value-added services that drive cost savings for its clients.

Claritev Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q4-2024)
|
% Change Since: 86.34%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic advancements, including successful debt refinancing, major contract wins, and product launches, which are offset by challenges such as a decline in revenue and dependence on a single client's performance. Overall, the company is optimistic about its future growth and transformation efforts, although it faces headwinds in its core business segments.
Q4-2024 Updates
Positive Updates
Successful Debt Refinancing
Claritev successfully refinanced its entire debt structure, extending maturities by approximately three years with a 99.75% participation outcome, demonstrating commitment to investors and confidence in the company's Vision 2030.
Record Contract Booking
Closed the largest-ever single contract booking of $34 million in total contract value, with 12 similar enterprise sale opportunities in the pipeline, indicating strong market demand and a new innovative business model.
New Product Launches and Market Expansion
Launched CompleteVue for providers and BenInsights for employers, with 39 new opportunities in the pipeline for 2025, contributing to market expansion and increased addressable market size.
Chief AI Officer Appointment
Appointed the first Chief AI Officer, underlining the company's commitment to technology and talent, with plans to leverage AI for product innovation and operational efficiencies.
Positive Client Renewal
Successfully renewed a major client for three additional years at the current value, reflecting the ongoing strength of core services and client relationships.
Negative Updates
Revenue Decline
FY 2024 revenue was $930.6 million, down 3.2% from FY 2023, primarily due to the impact of one large client, impacting overall financial performance.
Pressure on Core Business
Network-based revenues declined by 17.1%, and payment and revenue integrity revenues decreased by 1.6%, demonstrating challenges in maintaining growth in core segments.
Single-Client Impact
Continued challenges with a single client significantly affected revenue, with expectations for stabilization only by 2025, highlighting dependency on key clients.
Company Guidance
During the Claritev Corporation Fourth Quarter 2024 Earnings Call, CEO Travis Dalton and CFO Doug Garis provided guidance for 2025, highlighting a strategic focus on transformation and growth. They announced a revenue projection that is expected to be slightly down to flat for 2025, with an adjusted EBITDA margin target between 62.5% and 63.5%. The company anticipates a net revenue retention rate of approximately 97% for its core segments, despite the anticipated decline of one large client. Claritev expects strong double-digit growth in its HST and Data and Decision Science business areas, driven by a 20% growth in bookings. The company is also pursuing a Rule of 70 target, combining adjusted EBITDA margin and revenue growth percentage, as a medium- to long-term goal. With a focus on modernizing operations, Claritev aims to achieve a 10% to 15% cost reduction and improve its technology platform and business processes. The guidance reflects a strategy to balance cost efficiencies while pursuing new market opportunities and enhancing product offerings.

Claritev Financial Statement Overview

Summary
Claritev faces financial challenges with declining revenue, negative profitability, high leverage, and cash flow issues. The company needs to improve operational efficiency, reduce leverage, and enhance cash flow for sustainable growth and financial stability.
Income Statement
45
Neutral
Over the TTM period, the company has experienced a significant decline in profitability, with EBIT and EBITDA margins deeply negative. Revenue has declined slightly by 0.34% from the previous annual report, indicating challenges in sustaining growth. Historical data shows a trend of decreasing revenue and profit margins, making it imperative for the company to address operational inefficiencies and pursue growth initiatives.
Balance Sheet
30
Negative
The company's balance sheet reveals a high level of leverage, with a Debt-to-Equity ratio that has increased significantly due to declining equity. The Equity Ratio has deteriorated to a concerning level of 0.29%. This high leverage poses a financial risk if not managed carefully. The company needs to improve its equity position and manage debt levels to enhance its financial stability.
Cash Flow
40
Negative
The company's cash flow position is challenging, with negative free cash flow in the TTM period. The Operating Cash Flow has decreased significantly, and the Free Cash Flow to Net Income Ratio is negative, indicating cash flow issues. The company needs to focus on improving cash generation from operations and optimizing capital expenditures.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
927.45M930.62M961.52M1.08B1.12B937.76M
Gross Profit
687.68M691.22M726.06M875.62M942.31M619.09M
EBIT
-893.75M-1.39B161.98M-362.73M386.12M-131.82M
EBITDA
-523.35M-1.01B651.93M158.32M814.99M192.41M
Net Income Common Stockholders
-1.18B-1.65B-91.70M-572.91M102.08M-520.56M
Balance SheetCash, Cash Equivalents and Short-Term Investments
126.75M16.85M71.55M334.05M185.33M126.75M
Total Assets
8.28B5.15B6.96B7.37B8.22B8.28B
Total Debt
4.61B4.54B4.57B4.78B4.93B4.61B
Net Debt
4.49B4.52B4.50B4.45B4.74B4.49B
Total Liabilities
5.73B5.07B5.26B5.58B5.88B5.73B
Stockholders Equity
2.56B84.02M1.71B1.79B2.34B2.56B
Cash FlowFree Cash Flow
-98.60M-10.51M62.87M282.63M320.10M306.56M
Operating Cash Flow
27.84M107.62M171.72M372.36M404.69M377.37M
Investing Cash Flow
-126.44M-118.12M-249.79M-104.45M-228.38M-210.84M
Financing Cash Flow
63.32M-41.31M-180.99M-115.74M-114.68M-61.60M

Claritev Technical Analysis

Technical Analysis Sentiment
Positive
Last Price39.56
Price Trends
50DMA
25.13
Positive
100DMA
23.02
Positive
200DMA
16.15
Positive
Market Momentum
MACD
4.20
Negative
RSI
73.28
Negative
STOCH
85.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Positive. The current price of 39.56 is above the 20-day moving average (MA) of 31.34, above the 50-day MA of 25.13, and above the 200-day MA of 16.15, indicating a bullish trend. The MACD of 4.20 indicates Negative momentum. The RSI at 73.28 is Negative, neither overbought nor oversold. The STOCH value of 85.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTEV.

Claritev Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$451.61M-22.95%40.88%-579.73%
54
Neutral
$320.38M40.36%12.43%91.67%
54
Neutral
$420.01M-48.57%-100.00%83.98%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
51
Neutral
$386.50M-48.98%-9.95%20.78%
50
Neutral
$650.22M-198.69%-3.33%-86.58%
42
Neutral
$430.59M-30.10%-343.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTEV
Claritev
38.54
20.60
114.83%
HRTX
Heron Therapeutics
2.12
-1.57
-42.55%
BNTC
Benitec Biopharma
16.17
8.76
118.22%
TECX
Tectonic Therapeutic
24.48
6.72
37.84%
ETON
Eton Pharmaceuticals
15.85
12.25
340.28%
ABSI
AbSci
2.97
-1.55
-34.29%

Claritev Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
Claritev Shareholders Approve Omnibus Incentive Plan Amendment
Positive
May 1, 2025

On April 30, 2025, Claritev Corporation’s stockholders approved an amendment to the 2020 Omnibus Incentive Plan, increasing the shares reserved for issuance by 1,750,000. At the same annual meeting, stockholders elected three Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved executive compensation, indicating strong shareholder support for the company’s governance and strategic decisions.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.